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Abstract
In this minireview we describe the involvement of the atrial natriuretic peptide (ANP) in cardiovascular
pathophysiology and exercise. The ANP has a broad homeostatic role and exerts complex effects on the cardio-
circulatory hemodynamics, it is produced by the left atrium and has a key role in regulating sodium and water
balance in mammals and humans. The dominant stimulus for its release is atrial wall tension, commonly caused by
exercise. The ANP is involved in the process of lipolysis through a cGMP signaling pathway and, as a consequence,
reducing blood pressure by decreasing the sensitivity of vascular smooth muscle to the action of vasoconstrictors
and regulate fluid balance. The increase of this hormone is associated with better survival in patients with chronic
heart failure (CHF). This minireview provides new evidence based on recent studies related to the beneficial effects
of exercise in patients with cardiovascular disease, focusing on the ANP.
Background
The atrial natriuretic peptide (ANP) has a broad homeo-
static role and exerts complex effects on the cardio-cir-
culatory hemodynamics. It influences renal function and
lipid metabolism. Its discovery provided a powerful
blood propulsion pump to the heart, besides its impor-
tant endocrine functions. The ANP is produced from a
prohormone (pro-ANP), a molecule of 126 amino acids
secreted primarily by atrial myocytes after increased ten-
sion of the atrial wall [1].
The ANP is produced by the left atrium and has a key
role in regulating sodium and water balance in mam-
mals and humans [1,2]. The dominant stimulus for its
release is atrial wall tension, a frequent phenomenon
occurring during the changes that occur within the car-
diovascular exercise. In order to restore and maintain
cardiovascular homeostasis the heart synthesizes pep-
tides and hormones with diuretic, natriuretic and vaso-
dilator properties [3,4].
It was observed that concentrations of circulating
ANP increase during mild exercise, and during the
growing intensity of the maximum levels the concentra-
tion reach values up to two to three times higher. These
increased concentrations may be related to cardiac func-
tional impairment in people with chronic heart failure
(CHF) who are submitted to exercise, in which it was
observed that the concentration of this hormone was
more evident compared to healthy people [5]. Exercise
is a non-pharmacologic way to treat many cardiovascu-
lar diseases [6-9], hence, further studies investigating
non-pharmacological therapies such as exercise, are
always welcome in the literature.
In view of the above considerations, in this minireview
we described the involvement of the ANP in cardiovas-
cular pathophysiology and its relationship with exercise.
Method
The Medline (via PubMed), Lilacs and Scielo databases
were searched using the following subject keywords:
“Atrial natriuretic peptide,” “cardiovascular” and “patho-
physiology”. We also used the “related articles” function
on PubMed, Lilacs and Scielo, which allowed us to
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search the references of the studies that were retrieved
during our search. Publications were included in our
review if either their titles or abstracts were available in
English or Portuguese and suggested any effect (i.e.,
beneficial or malefic) or lack thereof from an anti-hyper-
tensive treatment on cardiac hypertrophy. The review
was completed on June, 2011. Publications were
excluded if the treatment was limited to a particular
technique or if the population received only one specific
procedure (drug treatment) associated with a disease
state or an age group. Other studies on anti-hyperten-
sive treatment for hypertensive patients that offered
additional relevant information found in the same data-
base were also examined. Each publication was reviewed
to identify the author(s), study period and data source,
which influenced us to include the reference in the
study.
Results and discussion
Table 1 shows the main studies related to pathophysio-
logical mechanisms of the ANP and its involvement in
physical exercise. ANP levels in patients with coronary
artery disease (CAD) are elevated, even in those treated
with beta-blockers (Pierre Yves marine). In addition,
individuals with CHF have elevated plasma levels of
peptides N-terminal (NT) and pro-atrial peptide (pro-
ANP) [10].
According to Moro et al [11], exercise stimulates the
production of ANP and hence lipolysis occurs via a
cGMP signaling pathway. Another study found that sub-
jects with CHF have high plasma levels of ANP also dur-
ing the exercises. However, the high amount of
circulating hormone is associated with a long maturity
[10]. The process of exercise-induced dehydration is
responsible for the increase of ANP induced by heat [12].
Acute infusion of pharmacological doses of ANP in
hypertensive individuals decreases cardiac output and
peripheral vascular resistance, suggesting an endogenous
physiological role [3]. With respect to molecular effects,
ANP stimulates the receptors of the plasma membrane
of fat cells (NPR-A subtype), promoting an intrinsic
activity of adenylate cyclase and increasing intracellular
levels of cGMP, which activates a cGMP-dependent
(PKG) phosphorylation of perilipin and HSL that stimu-
late lipolysis [13,14]. Moreover, within a physiological
range, the ANP stimulates adipose tissue lipolysis, fat
oxidation, and increases circulating levels of non esteri-
fied fatty acids (NEFA) [3].
Recent studies have shown that proANP1 and
proANP31-30-67 exert a strong action on renal function
through increased beta2-microglobulin, albumin and
total protein excretion and inhibition of proximal tubu-
lar reabsorption [15]. Another important aspect is that
when the intensity of exercise is increased, the blood
flow decreases in the kidney in order to prevent dehy-
dration, however, the water retention increases in the
kidney. Moreover, after exercising a lot of protein
comes from the circulation to the kidney, which comes
from both the degradation of proteins damaged during
exercise and negative nitrogen balance. Thus, the
proANP proteirunic answer could be one mechanism to
help the kidneys to excrete this amount of protein, pro-
tecting it from damage and dysfunction [1].
As mentioned above, the ANP is a hormone found in
increasing concentrations in patients with CHF and is
associated with functional impairment. There are some
studies reporting increased plasma levels of ANP in
response to dynamic exercise in these patients and lack
of conditioning may be an important aggravating factor
in the pathophysiology underlying the exercise [10].
During exercise, there is a high release of ANP in atrial
secretory granules [10,16]. Nevertheless, patients with
CAD have increased release of ANP when treatment
includes beta-blockers. This secretion of vasodilatory
and natriuretic constitutes a unique system for protect-
ing the heart against stress [17].
The pro-ANP levels increased gradually in patients
with CHF after doing exercises. The degree of increase
in this hormone was obtained during exercise tests, and
the result was associated with better survival in this
population. These findings may represent a potential
beneficial effect of increasing the capacity of ANP in
CHF patients after completion of exercise [10]. In a pre-
vious study it was conducted a test exercise for 50 min-
utes at 60% VO2max and resting heat exposure. The
results confirmed the significant increase in the amount
Table 1 Summary of the main studies regarding ANP and exercise.
Author and year Main findings
Moro et al, 2004
[13]
Physical exercise induces the release of ANP, which stimulates lipolysis through a cGMP signaling pathway.
Larsen et al, 2003
[10]
Patients with chronic heart failure present an elevated plasma level of N-terminal peptide (NT) and pro-atrial peptide (pro-
ANP) compared with healthy people.
Marie et al, 2004
[4]
Patients with coronary artery disease present high levels of ANP when treated with beta blockers.
Melin et al, 2001
[11]
During the process of exercise-induced dehydration there was a significant increase of ANP in relation to passively induced
by heat.
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of circulating ANP, confirming the action of this hor-
mone in the renal system after completion of exercise
[12].
Exercise is accepted as a strong stimulus for the
release of alpha ANP. The dominant stimulus for its
release is the atrial wall tension, a frequent phenomenon
that occurs during exercise [1,17,18]. In addition, it was
demonstrated that proANPs are deeply related to other
hormonal systems involved in physical exercise
[1,10,12,19]. A study measured the urinary levels of
proANP1-30-67 and proANP31 before and after strenu-
ous exercise. They showed that urinary levels of
proANP1-30 were not different between before and
after exercise, while pro ANP31-urinary-67 showed a
significant increase [1].
ANP reduces blood pressure by decreasing the sensitiv-
ity of vascular smooth muscle to the action of vasocon-
strictors and regulate fluid balance. This secretion of
potent vasodilating and natriuretic agents constitutes an
original therapeutic mechanism for the protection of
heart disease and cardiac stress though high for both
peptides (ANP and BNP) in patients with heart failure
and more limited in normal subjects [4]. On the other
hand, according to previous studies, the elevation of ANP
at rest was associated with a higher risk of mortality. The
increase during the exercise test was associated with bet-
ter survival in the study population, indicating a physiolo-
gical benefit and an efficient mechanism to increase the
ability of ANP during exercise in patients with CHF.
Therefore, although several studies show an association
between elevated levels of ANP and disease progression
in patients with CHF, it was suggested that this neuro-
hormone is a prognostic marker, which may also mediate
the effects of the benefit these patients [10].
Some findings were observed in studies of patients
with cardiovascular disease, especially congestive heart
failure (CHF), where it was selected 25 patients with
coronary artery disease, they were submitted to exercise
stress test on a treadmill, and after blood collection and
analysis, the presence of pre ANP hormone, increased in
concentration by increasing the survival of these patients
[10]. In patients with chronic CAD, the average concen-
tration of ANP was two times higher than in normal
subjects after exercises and use of beta-blockers [17].
Although it is necessary further studies regarding the
cardiac function and its relationship with the ANP, the
ANP function presents itself as an indicator of the
degree of functionality of cardiac function in patients
with cardiac disease in particular. The presence of this
circulating hormone may be a preventive tool in the
development of chronic diseases related to the cardio-
vascular system [10].
The ANP also inhibits the function of various other
hormones such as aldosterone, angiotensin II,
endothelin, renin and vasopressin. In the kidneys, it
inhibits the absorption of sodium in the collecting ducts
of nephrons, it inhibits the action of aldosterone and
counteracts the renin-angiotensin-aldosterone system.
Consequently, it increases excretion of sodium. As a
consequence, water follows sodium because of osmosis.
The alfa ANP with other proANP fragments (proANPs)
exerts a strong influence on renal function. In fact, it
increases glomerular filtration rate, inhibiting the NAQ
transport and increase the volume of urine and excre-
tion of protein [1,3,15]. In a study of 28 athletes cyclists,
urine samples were collected before and after the test
and the result was positive for a high concentration of
fragments of the pro-hormone (pro ANP1 pro-30 and
31-67) with other proteins, which has a strong influence
on the renal system, increasing the rate of glomerular
filtration. The reason for this is that these particular
pre-hormones have effects on specific binding region of
the medullary duct, and increased physical effort prac-
ticed by cyclists increased renal filtration increases,
occurring an abrupt overload, but the high concentra-
tion of ANPs facilitates the filtration rate of many pro-
teins because its vasodilator effect and decreasing renal
overload [18].
In addition to catecholamines, insulin and ANP are
essential physiological regulators of lipolysis of human
adipocytes [3,20]. It was demonstrated in a study that
the physiological release of ANP during the acute physi-
cal exercise contributes to the stimulation of lipid mobi-
lization and supply of NEFA to the working muscles
[21]. Some studies have shown higher levels of ANP at
rest in trained animals and humans [22] and others did
not report any effect of training [12].
Patients with CHF have high level of N-terminal pep-
tide (NT) and pro-atrial peptide (pro-ANP) in plasma
compared with healthy people, and this neuro-hormone
concentration is even higher during exercise, which can
be associated with better survival in this population,
suggesting a great benefit and increased potential to
increase the amount of ANP [10]. Furthermore, patients
with CAD have increased concentrations of ANP after
conducting exercises when they are treated with beta-
blockers. This secretion of potent vasodilating and
natriuretic agents constitutes an original therapeutic
mechanism for protection of the diseased heart against
stress. During exercise, the release of secretory granules
allows ANPs by an immediate increase in blood levels of
this neurohormone. These granules are located mainly
in atrial myocytes, but also located in ventricular myo-
cytes in patients with congestive heart failure [17]. In
addition, during the processes of dehydration, plasma
ANP increased significantly during exercise-induced
dehydration, whereas it did not change during passive
heat-induced dehydration [12]. Nonetheless, more
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studies are necessary to better understand the exact role
of exercise in proANP fragment. In particular, proANP1,
proANP31-30-67 and urinary tract can contribute to a
long-term local involvement of ANP in the regulation of
kidney function [3].
Concluding Remarks
Our review provides new evidence based on recent stu-
dies related to the beneficial effects of exercise in
patients with cardiovascular disease, focusing on the
ANP. This minireview does not allow us to accurately
identify all the mechanisms involved in changes in
plasma ANP levels induced by exercise. The current lit-
erature shows a direct correlation between the release of
ANP induced by exercise and reduced cardiovascular
mortality. Further studies investigating non-pharmacolo-
gical therapies such as exercise, are always welcome in
the literature.
Author details
1Departamento de Morfologia e Fisiologia, Faculdade de Medicina do ABC.
Av. Príncipe de Gales, 821. 09060-650, Santo André, SP, Brazil. 2Escola de
Artes, Ciência e Humanidades da Universidade de São Paulo (USP). Rua
Arlindo Béttio, 1000, São Paulo, SP. 03828-000, Brazil. 3Departamento de
Fisioterapia, Faculdade de Ciências e Tecnologia, Universidade Estadual
Paulista, UNESP. Rua Roberto Simonsen, 305. 19060-900, Presidente Prudente,
São Paulo, Brazil. 4Departamento de Saúde Coletiva, Universidade Federal do
Acre. Campus Universitário, BR 364, Km 04. 69915-900, Rio Branco, AC, Brasil.
5Departamento de Fonoaudiologia, Faculdade de Filosofia e Ciências,
Universidade Estadual Paulista, UNESP. Av. Higyno Muzzi Filho, 737. 17.525-
900, Marília, SP, Brazil.
Authors’ contributions
All authors participated in the acquisition of data and revision of the
manuscript. All authors conceived of the study, determined the design,
performed the statistical analysis, interpreted the data and drafted the
manuscript. All authors read and gave final approval for the version
submitted for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 14 September 2011 Accepted: 7 February 2012
Published: 7 February 2012
References
1. Cappellin E, De Palo EF, Gatti R, Solda G, Woloszczuk W, Spinella P: Effect of
prolonged physical exercise on urinary proANP1-30 and proANP31-67.
Clin Chem Lab Med 2004, 42:1058-1062, 2004.
2. Moro C, Pasarica M, Elkind-Hirsch K, Redman LM: Aerobic Exercise Training
Improves Atrial Natriuretic Peptide and Catecholamine-Mediated
Lipolysis in Obese Women with Polycystic Ovary Syndrome. J Clin
Endocrinol Metab 2009, 94:2579-2586, 2009.
3. Engelmamm MD, Niemamm L, Kanstrup IL, Skagen K, Goldtfrendsen J:
Natriuretc peptide response to dynamic exercise in patients with atrial
fibrillation. In J Cardiol 2005, 105:31-9.
4. Marie PY, Mertes PM, Hassan-Sebbag N, Talence N, Djaballah K, Djaballah W,
Friberg J, Olivier P, Karcher G, Zannad F, Bertrand A: Exercise Release of
Cardiac atriuretic Peptides Is Markedly Enhanced When Patients With
Coronary Artery Disease Are Treated Medically by Beta-Blockers. J Am
Col Cardiol 2004, 43:353-359.
5. Heringlake M, Kox T, Poeling J, Klaus S, Hanke T, Franz N, Heberhadt F,
Heinze H, Hahblrmann L: The effects of physical exercise on plasma
levels of relaxin. NT pro ANP, and NT pro BNP in patients with ischemic
heart disease. Eur J Med Res 2009, 14:106-12.
6. Ferreira M, Santos-Silva PR, de Abreu LC, Valenti VE, Crispim V, Imaizumi C,
Filho CF, Murad N, Meneghini A, Riera AR, de Carvalho TD, Vanderlei LC,
Valenti EE, Cisternas JR, Moura Filho OF, Ferreira C: Sudden cardiac death
athletes: a systematic review. Sports Med Arthrosc Rehabil Ther Technol
2010, 2:19.
7. Quilici BC, Gildo C Jr, de Godoy JM, Quilici BS, Augusto CR: Comparison of
reduction of edema after rest and after muscle exercises in treatment of
chronic venous insufficiency. Int Arch Med 2009, 2:18.
8. Abdou M: Myocardial bridging causing ischemia and recurrent chest
pain: a case report. Int Arch Med 2011, 4:24.
9. Bösner S, Haasenritter J, Becker A, Hani MA, Keller H, Sönnichsen AC,
Karatolios K, Schaefer JR, Baum E, Donner-Banzhoff N: Heartburn or
angina? Differentiating gastrointestinal disease in primary care patients
presenting with chest pain: a cross sectional diagnostic study. Int Arch
Med 2009, 2:40.
10. Larsen AI, Hall C, Aukrust P, Aarsland T, Faris P, Dickstein K: Prognostic
Usefulness of an Increase of N-Terminal Proatrial Natriuretic Peptide
During Exercise in Patients With Chronic Heart Failure. Am J Cardiol 2003,
92:91-94.
11. Melin B, Koulmann N, Jimenez C, Savourey G, Launay JC, Cottet-Emard JM,
Pequignot JM, Allevard AM, Gharib C: Comparison of passive heat or
exercise-induced dehydration on renal water and electrolyte excretion:
the hormonal involvent. Eur J Appl Physiol 2001, 85:250-258.
12. Moro C, Pillard F, Glisezinski I, Klimcakova E, Crampes F, Thalamas C,
Harant I, Marques MA, Lafontan M, Berlan M: Exercise-induced lipid
mobilization in subcutaneous adipose tissue is mainly related to
natriuretic peptides in overweight men. Am J Physiol Endocrinol Metab
2008, 295:505-513.
13. Moro C, Cramps F, Sengenes C, De Glisezinski I, Galitziky J, Thalamas C,
Lafontan M, Berlan M: Atrial natriuretc peptides contributes to
physiological of lipid mobilization in humans. FASEB J 2004, 18:908-10.
14. Moro C, Polak J, Hejnova J, Klimcakova E, Crampes F, Stich V, Lafontan M,
Berlan M: Atrial natriuretic peptide stimulates lipid mobilization during
repeated bouts of endurance exercise. Am J Physiol Endocrinol Metab
2006, 290:864-869.
15. Ykeda N, Yasu T, Nishikimi T, Nakamura T, Kubo N, Kavakami M,
Momomura S, Saito M: N- Terminal pro-atrial natriuretic peptide end
exercice prescription in patients whit myocardial infraction. Regul pept
2007, 141:154-8.
16. Bentzen H, Pedersen RS, Nyvad O, Pedersen EB: Effect of exercise on
natriuretic peptides in plasma and urine in chronic heart failure. Int J
Cardiol 2004, 93:121-130.
17. Marie PY, Martes PM, Hassan-Sebbag N, de Talence N, Djaballah W,
Friberg J, Oliver P, Karcher G, Zannad F, Bertrand A: Exercise Release of
cardiac peptides is markedly enhanced when patients with coronary
artery disease are treated medically by beta-blckers. J Am Coll Cardiol
2004, 43:353-9.
18. Durand F, Mucci P, Hayot M, Couret I, Bonnardet A, Prefaut CH: Attenuated
ANF response to exercisein athletes with exercise-induced hypoxemia.
Int J Sports Med 2004, 25:252-256.
19. Pawilicki L, Irzmansk R, Rózalski J, Kokot F: Correlation between left
ventricular mass and the resting and post-exercise release of ANP in
healthy men. Med Sci Monit 2001, 7:903-7.
20. De Pasquale CG, Arnolda LF, Doyle IR, Aylward PE, Russell AE, Bersten AD:
Circulating surfactant protein-B levels increase acutely in response to
exercise-induced left ventricular dysfunction. Clin Exp Pharmacol Physiol
2005, 32:622-627.
21. Moro C, Pillard F, De Glisezinsk I, Harant I, Rivière D, Stich V, Lafontan M,
Crampes F, Berlan M: Traning enhances ANP lipid-mobilizing action in
adipose tissue of ouverweith man. Med Sci Sports Exerc 2005, 37:1126-32.
22. Betzen H, Pdersen RS, Nivad O, Pedersen EB: Influense of traning habits on
exercise-induced changes in plasma atrial brain natriuretic peptide and
urinary excretion of aquaporin-2 in healthy man. Scan J Clin Lab Invest
2002, 62:541-51.
doi:10.1186/1755-7682-5-4
Cite this article as: de Almeida et al.: Involvement of the atrial
natriuretic peptide in cardiovascular pathophysiology and its
relationship with exercise. International Archives of Medicine 2012 5:4.
de Almeida et al. International Archives of Medicine 2012, 5:4
http://www.intarchmed.com/content/5/1/4
Page 4 of 4
